True Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

True Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1.09M	Sell	8,433 -23	-0.3%	-$3.01K	0.75%	33
2022 Q4	$1.11M	Buy	+8,456	New	+$1.09M	0.9%	29

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

True Capital Management's IBB Position: Q1 2023 in Review

True Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 0.27% in Q1 2023, selling an estimated $3.01K and leaving 8,433 shares worth $1.09M. The position accounts for 0.75% of the portfolio, ranked #33.

True Capital Management first reported a position in IBB in Q4 2022 and has held it in 2 quarters since. The position peaked at $1.11M in Q4 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

True Capital Management held 8,433 shares of iShares Biotechnology ETF worth $1.09M as of Q1 2023.
True Capital Management sold 23 iShares Biotechnology ETF shares in Q1 2023, an estimated $3.01K.
iShares Biotechnology ETF made up 0.75% of True Capital Management's portfolio in Q1 2023, its #33 holding.
True Capital Management first reported a position in iShares Biotechnology ETF in Q4 2022 and has held it in 2 quarters since.
True Capital Management's iShares Biotechnology ETF position peaked at $1.11M in Q4 2022.
866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on True Capital Management's 13F filing for Q1 2023, filed 2 May 2023.